The PI3K–AKT pathway provides good therapeutic responses in clinical trials (Britten 2013), and the activation of PI3K–AKT pathway has a critical role in providing an alternative survival pathway in cancer cells (Hoeflich et al. 2009). The gene discussed is AKT1; the disease is cancer.